Can Organon cover its short-term obligations?

Its current ratio is 1.97 — current assets exceed current liabilities.

Where does Organon's balance sheet data come from?

Every line is extracted from Organon's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Organon OGN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$574M-15.0%	$675M-2.6%	$693M-1.8%	$706M-4.2%
Accounts receivable, net	$5.76B-7.3%	$6.21B-4.6%	$6.51B+13.7%	$5.73B+6.1%
Inventories	$930M+66.4%	$559M+42.6%	$392M+21.0%	$324M+16.5%
Raw materials	$14M-44.0%	$25M-77.3%	$110M+150%	$44M-53.7%
Work in process	$791M+17.2%	$675M-1.3%	$684M+13.8%	$601M+22.7%
Finished goods	$751M-1.7%	$764M+35.0%	$566M+17.4%	$482M+27.9%
Prepaid expenses and other current assets	$1.03B+3.9%	$994M+31.5%	$756M+1.2%	$747M+2.9%
Assets held for sale	$8M—	$0—	——	——
Materials and supplies	$81M+2.5%	$79M+21.5%	$65M+47.7%	$44M+10.0%
Total current assets	$4.35B+0.1%	$4.35B-3.5%	$4.51B+14.7%	$3.93B+4.5%
Property and equipment, net	$1.3B+11.6%	$1.17B-1.3%	$1.18B+16.2%	$1.02B+4.6%
Goodwill	$4.15B-11.3%	$4.68B+1.7%	$4.6B0.0%	$4.6B0.0%
Intangible assets, net	$1.13B-20.1%	$1.41B+165%	$533M-17.9%	$649M-0.3%
Deferred tax assets	$257M+9.8%	$234M+53.9%	$152M+74.7%	$87M-66.4%
Other non-current assets	$1.54B+3.2%	$1.49B+21.1%	$1.23B+63.3%	$754M+8.6%
Total assets	$12.87B-1.8%	$13.1B+8.6%	$12.06B+10.1%	$10.96B+2.6%
Accounts payable	$952M-17.4%	$1.15B-12.3%	$1.31B+16.1%	$1.13B-18.1%
Current portion of long-term debt	$16M-20.0%	$20M+122%	$9M+12.5%	$8M-11.1%
Liabilities held for sale	$2M—	$0—	——	——
Income taxes payable	$571M-25.0%	$761M+5.4%	$722M-11.3%	$814M-20.7%
Total current liabilities	$2.39B-12.1%	$2.72B-6.9%	$2.92B+16.2%	$2.51B-3.3%
Long-term debt	$8.63B-2.6%	$8.86B+1.2%	$8.75B-1.7%	$8.91B-2.4%
Other non-current liabilities	$1.01B+3.2%	$977M+137%	$412M+0.2%	$411M-11.2%
Total liabilities	$12.12B-4.1%	$12.63B+4.1%	$12.13B+2.4%	$11.85B—
Common stock	500M+16,567%	3M0.0%	3M0.0%	3M0.0%
Additional paid-in capital	$167M+54.6%	$108M+332%	$25M—	$0—
Retained earnings	$1.11B+9.8%	$1.01B+128%	$443M+234%	-$331M+66.8%
Accumulated other comprehensive income (loss)	-$527M+18.8%	-$649M-20.0%	-$541M+4.1%	-$564M-9.9%
Total stockholders' equity	$752M+59.3%	$472M+774%	-$70M+92.2%	-$892M+40.8%
Total liabilities and stockholders' equity	$12.87B-1.8%	$13.1B+8.6%	$12.06B+10.1%	$10.96B+2.6%
Accounts Receivable Derecognized	$217M+16.7%	$186M+182%	$66M+53.5%	$43M-50.6%
Allowance for Doubtful Accounts	$12M-14.3%	$14M+55.6%	$9M0.0%	$9M+28.6%
Allowance for Doubtful Accounts Receivable (Current)	$12M-14.3%	$14M+55.6%	$9M0.0%	$9M+28.6%
Other current assets	$1.03B+3.9%	$994M+31.5%	$756M+1.2%	$747M+2.9%
Inventory LIFO Reserve	$114M-14.3%	$133M+26.7%	$105M+36.4%	$77M+48.1%
Deferred Tax Assets and Other Non-Current Assets	$1.54B+3.2%	$1.49B+21.1%	$1.23B+63.3%	$754M+3,042%
Intangible assets — net	$1.13B-20.1%	$1.41B+165%	$533M-17.9%	$649M-0.3%
Accrued Litigation	$10M+42.9%	$7M-65.0%	$20M+17.6%	$17M+88.9%
Accrued and other current liabilities	$1.34B-5.4%	$1.41B+1.6%	$1.39B+16.9%	$1.19B+16.4%
Accrued Income Taxes, Current	$85M-36.6%	$134M-35.0%	$206M+12.0%	$184M-0.5%
Restructuring Reserve	$8M-42.9%	$14M-77.0%	$61M+205%	$20M—
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$81M-16.5%	$97M+15.5%	$84M-20.0%	$105M-15.3%
Total debt	$8.8B-2.6%	$9.04B+1.2%	$8.93B-2.0%	$9.11B-2.7%
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	260.3M+1.0%	257.8M+0.9%	255.6M+0.5%	254.4M+0.3%
Additional paid-in capital	$167M+54.6%	$108M+332%	$25M—	$0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$3M0.0%	$3M0.0%	$3M0.0%	$3M0.0%
Number of Exercisable Options	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	7.5M+8.2%	6.9M-99.9%	5.8B+21.8%	4.7B+7.6%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Weighted Average Exercise Price of Exercisable Options	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$27.30-7.3%	$29.44-8.6%	$32.20-6.2%	$34.340.0%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——
Allowance for doubtful accounts	$12M-14.3%	$14M+55.6%	$9M0.0%	$9M+28.6%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M0.0%	$500M0.0%
Common stock, shares issued (in shares)	$260.32M+1.0%	$257.8M+0.9%	$255.63M+0.5%	$254.37M+0.3%
Common Stock, Shares, Outstanding	$260.32M+1.0%	$257.8M+0.9%	$255.63M+0.5%	$254.37M+0.3%
Short-term debt and current portion of long-term debt	$16M-20.0%	$20M—	——	——
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$81M-16.5%	$97M+15.5%	$84M-20.0%	$105M-15.3%
Deferred income taxes	$57M-23.0%	$74M+57.4%	$47M+147%	$19M+375%
Unrecognized compensation cost related to non-vested awards	——	——	——	——
Inventory Net And Inventory Noncurrent	$1.64B+6.9%	$1.54B+7.8%	$1.43B+23.8%	$1.15B+16.1%
Raw materials	$14M-44.0%	$25M-77.3%	$110M+150%	$44M-53.7%
Liabilities of discontinued operations (Note 2)	$32M—	$0—	——	——
Estimated litigation liability	$10M+42.9%	$7M-65.0%	$20M+17.6%	$17M+88.9%
2028	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Thereafter	——	——	——	——
Number of manufacturing facilities	——	——	——	——
Number of medicines and products	——	——	——	——
Number of shareholder derivative lawsuits filed	——	——	——	——
Restructuring Reserve	$8M-42.9%	$14M-77.0%	$61M+205%	$20M—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$7.52M+8.2%	$6.95M-99.9%	$5.76B+21.8%	$4.73B+7.6%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$27.3-7.3%	$29.44-8.6%	$32.2-6.2%	$34.340.0%
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price	$6.99-9.2%	$7.70-9.5%	$8.51-4.5%	$8.91+3.2%
Accounts receivable, derecognized	$217M+16.7%	$186M+182%	$66M+53.5%	$43M-50.6%
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Organon cover its short-term obligations?: Its current ratio is 1.97 — current assets exceed current liabilities.
Where does Organon's balance sheet data come from?: Every line is extracted from Organon's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.